MedTrace Logo

Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia

NCT03703271 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2022-07-18

No results posted yet for this study

Summary

Study of hysteroscopic repeat curettage as the first-line treatment in low-risk postmolar gestational trophoblastic neoplasia compared with the MTX single drug chemotherapy

Conditions

  • Gestational Trophoblastic Neoplasia

Interventions

DRUG

Methotrexate

single-agent 5-day methotrexate, two weeks a cycle

PROCEDURE

hysteroscopic repeat curettage

Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Women's Hospital School Of Medicine Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03703271 on ClinicalTrials.gov